Selpercatinib, a highly selective oral, CNS penetrant RET inhibitor, was assessed in the phase I/II LIBRETTO 001 trial in patients with advanced NSCLC with RET rearrangements [199]. This evidence concerns the gene RET and non-small cell lung carcinoma.